/stocks — the workspaceLOADING
Eikon Therapeutics, Inc. (EIKN) is a biological products, (no diagnostic substances) company. Fundamentals from SEC filings; prices are end-of-day.
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
A plain-English read on EIKN plus an auto-SWOT — built from EIKN's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate EIKN using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| Column Group IV GP, LP10% owner | BUY | $38.1M | view → |
| Lux Venture Partners V, LLCDirector | BUY | $5.0M | view → |
| Wolfe JoshDirector | BUY | $5.0M | view → |
| FRAZIER KENNETH CDirector | BUY | $2.0M | view → |
| Foresite Capital Management IV, LLC10% owner | BUY | $1000K | view → |
Projected from EIKN's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment EIKN files its announcement.
| Reported | Close-to-close |
|---|---|
| 2026-05-11 | +15.8% |
| 2026-03-30 | +7.8% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.